GenMont Biotech Incorporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 76.36 million compared to TWD 76.08 million a year ago. Net income was TWD 23.88 million compared to TWD 8.12 million a year ago. Basic earnings per share from continuing operations was TWD 0.28 compared to TWD 0.09 a year ago. Diluted earnings per share from continuing operations was TWD 0.28 compared to TWD 0.09 a year ago.
For the nine months, sales was TWD 243.91 million compared to TWD 262.53 million a year ago. Net income was TWD 35.01 million compared to TWD 43.13 million a year ago. Basic earnings per share from continuing operations was TWD 0.41 compared to TWD 0.5 a year ago. Diluted earnings per share from continuing operations was TWD 0.4 compared to TWD 0.5 a year ago.